Hims & Hers Health is trading 3.54% higher at €26.34, but the reason for the increase remains unclear.
- October 5 coverage noted securities class-action reminders concerning earlier allegations; they were not a new ruling or resolution.
- J.P. Morgan initiated coverage with a Hold rating, but available sources do not link either item to the move.
- Provided market data showed modest futures gains and flat major indexes. No reliable volume or activity details were found.